SELLAS Life Sciences Group, Inc. Earnings Per Share, Basic and Diluted
SELLAS Life Sciences Group, Inc. (SLS) reported Earnings Per Share, Basic and Diluted of -$0.16 per share for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2021-05-13
- SELLAS Life Sciences Group, Inc. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.16.
- SELLAS Life Sciences Group, Inc. earnings per share, basic and diluted for the quarter ending 2020-12-31 was -$0.36.
- SELLAS Life Sciences Group, Inc. earnings per share, basic and diluted for the quarter ending 2020-09-30 was -$0.53.
- SELLAS Life Sciences Group, Inc. earnings per share, basic and diluted for the quarter ending 2020-06-30 was -$0.66.
- SELLAS Life Sciences Group, Inc. earnings per share, basic and diluted for fiscal 2020 was -$2.11.
- SELLAS Life Sciences Group, Inc. earnings per share, basic and diluted for fiscal 2019 was -$10.92.
- SELLAS Life Sciences Group, Inc. earnings per share, basic and diluted for fiscal 2018 was -$157.72.
- SELLAS Life Sciences Group, Inc. earnings per share, basic and diluted for fiscal 2017 was -$10.44.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 3 month as first filed | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 6 month as first filed | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 9 month as first filed | Earnings Per Share, Basic and Diluted 12 month | Earnings Per Share, Basic and Diluted 12 month as first filed | Earnings Per Share, Basic and Diluted 108 month |
|---|---|---|---|---|---|---|---|---|---|
| 2021-03-31 | -$0.16 10-Q · filed 2021-05-13 | -$0.48 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$0.94 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$1.49 derived: net income ÷ weighted average shares · filed 2022-03-31 | |||||
| 2020-12-31 | -$0.36 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$0.87 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$1.48 derived: net income ÷ weighted average shares · filed 2022-03-31 | -$2.11 10-K · filed 2021-03-23 | |||||
| 2020-09-30 | -$0.53 10-Q · filed 2020-11-13 | -$1.18 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$1.83 10-Q · filed 2020-11-13 | -$3.12 derived: net income ÷ weighted average shares · filed 2021-11-12 | |||||
| 2020-06-30 | -$0.66 10-Q · filed 2020-08-13 | -$1.32 10-Q · filed 2020-08-13 | -$2.69 derived: net income ÷ weighted average shares · filed 2021-08-12 | -$4.96 derived: net income ÷ weighted average shares · filed 2021-08-12 | |||||
| 2020-03-31 | -$0.66 10-Q · filed 2021-05-13 | -$2.08 derived: net income ÷ weighted average shares · filed 2021-05-13 | -$4.48 derived: net income ÷ weighted average shares · filed 2021-05-13 | -$6.75 derived: net income ÷ weighted average shares · filed 2021-05-13 | |||||
| 2019-12-31 | -$1.54 derived: net income ÷ weighted average shares · filed 2021-03-23 | -$4.15 derived: net income ÷ weighted average shares · filed 2021-03-23 | -$7.07 derived: net income ÷ weighted average shares · filed 2021-03-23 | -$10.92 10-K · filed 2021-03-23 | |||||
| 2019-09-30 | -$2.68 10-Q · filed 2020-11-13 | -$6.31 derived: net income ÷ weighted average shares · filed 2020-11-13 | -$11.37 10-Q · filed 2020-11-13 | -$23.30 derived: net income ÷ weighted average shares · filed 2020-11-13 | |||||
| 2019-06-30 | -$6.33 10-Q · filed 2020-08-13 | -$0.13 10-Q · filed 2019-08-14 | -$16.56 10-Q · filed 2020-08-13 | -$0.33 10-Q · filed 2019-08-14 | -$43.90 derived: net income ÷ weighted average shares · filed 2020-08-13 | -$67.61 derived: net income ÷ weighted average shares · filed 2020-08-13 | |||
| 2019-03-31 | -$11.12 10-Q · filed 2020-05-14 | -$0.22 10-Q · filed 2019-05-15 | -$41.41 derived: net income ÷ weighted average shares · filed 2020-05-14 | -$67.28 derived: net income ÷ weighted average shares · filed 2020-05-14 | -$18.12 derived: net income ÷ weighted average shares · filed 2020-05-14 | ||||
| 2018-12-31 | -$30.52 derived: net income ÷ weighted average shares · filed 2020-03-13 | -$57.67 derived: net income ÷ weighted average shares · filed 2020-03-13 | -$12.42 derived: net income ÷ weighted average shares · filed 2020-03-13 | -$157.72 10-K · filed 2020-03-13 | -$3.15 10-K · filed 2019-03-22 | ||||
| 2018-09-30 | -$26.75 10-Q · filed 2019-11-14 | -$0.53 10-Q · filed 2018-11-14 | -$5.05 derived: net income ÷ weighted average shares · filed 2019-11-14 | -$137.43 10-Q · filed 2019-11-14 | -$2.75 10-Q · filed 2018-11-14 | -$11.89 derived: net income ÷ weighted average shares · filed 2019-11-14 | |||
| 2018-06-30 | -$1.26 10-Q · filed 2019-08-14 | -$2.89 10-Q · filed 2019-08-14 | -$6.86 derived: net income ÷ weighted average shares · filed 2019-08-14 | -$9.14 derived: net income ÷ weighted average shares · filed 2019-08-14 | |||||
| 2018-03-31 | -$1.67 10-Q · filed 2019-05-15 | -$7.11 derived: net income ÷ weighted average shares · filed 2019-05-15 | -$9.65 derived: net income ÷ weighted average shares · filed 2019-05-15 | -$13.64 derived: net income ÷ weighted average shares · filed 2019-05-15 | |||||
| 2017-12-31 | $19.24 derived: net income ÷ weighted average shares · filed 2019-03-22 | -$18.92 derived: net income ÷ weighted average shares · filed 2019-03-22 | -$21.36 derived: net income ÷ weighted average shares · filed 2019-03-22 | -$10.44 10-K · filed 2019-03-22 | |||||
| 2017-09-30 | -$2.27 10-Q · filed 2018-11-14 | -$6.33 derived: net income ÷ weighted average shares · filed 2018-11-14 | -$4.56 10-Q · filed 2018-11-14 | ||||||
| 2017-06-30 | -$4.50 10-Q · filed 2018-08-14 | -$8.14 10-Q · filed 2018-08-14 | |||||||
| 2017-03-31 | -$3.63 10-Q · filed 2018-05-15 | ||||||||
| 2016-12-31 | -$18.66 10-K · filed 2018-04-13 | -$2.36 10-K · filed 2017-03-15 | |||||||
| 2015-12-31 | -$8.23 10-K · filed 2017-03-15 | -$0.41 10-K · filed 2016-03-10 | |||||||
| 2015-06-30 | -$0.10 10-Q · filed 2015-08-06 | -$0.18 10-Q · filed 2015-08-06 | |||||||
| 2015-03-31 | -$0.08 10-Q · filed 2015-05-07 | ||||||||
| 2014-12-31 | -$6.13 10-K · filed 2017-03-15 | -$0.31 10-K · filed 2015-03-05 | |||||||
| 2014-09-30 | -$0.05 10-Q · filed 2014-11-05 | -$0.24 10-Q · filed 2014-11-05 | |||||||
| 2014-06-30 | -$0.17 10-Q · filed 2015-08-06 | -$0.19 10-Q · filed 2015-08-06 | |||||||
| 2014-03-31 | -$0.02 10-Q · filed 2015-05-07 | ||||||||
| 2013-12-31 | -$0.85 10-K/A · filed 2016-04-15 | ||||||||
| 2013-09-30 | -$0.11 10-Q · filed 2014-11-05 | -$0.33 10-Q · filed 2014-11-05 | |||||||
| 2013-06-30 | -$0.11 10-Q · filed 2014-08-11 | -$0.23 10-Q · filed 2014-08-11 | |||||||
| 2013-03-31 | -$0.11 10-Q · filed 2014-05-06 | ||||||||
| 2012-12-31 | -$0.56 8-K · filed 2015-12-04 | ||||||||
| 2012-09-30 | -$0.09 10-Q/A · filed 2013-11-07 | -$0.52 10-Q/A · filed 2013-11-07 | |||||||
| 2012-03-31 | -$0.52 10-Q · filed 2012-05-14 | ||||||||
| 2011-12-31 | -$0.32 10-K · filed 2014-03-17 | $0.00 10-K · filed 2012-03-28 | |||||||
| 2011-09-30 | -$0.14 10-Q · filed 2012-11-13 | -$0.13 10-Q · filed 2011-11-14 | -$0.41 10-Q · filed 2012-11-13 | -$0.39 10-Q · filed 2011-11-14 | |||||
| 2011-06-30 | -$0.11 10-Q · filed 2012-08-14 | -$0.04 10-Q · filed 2011-08-15 | -$0.27 10-Q · filed 2012-08-14 | -$0.18 10-Q · filed 2011-08-15 | |||||
| 2011-03-31 | -$0.19 10-Q · filed 2012-05-14 | ||||||||
| 2010-12-31 | -$0.67 10-K · filed 2012-03-28 | ||||||||
| 2010-09-30 | -$0.23 10-Q · filed 2011-11-14 | -$0.57 10-Q · filed 2011-11-14 | |||||||
| 2010-06-30 | -$0.12 10-Q/A · filed 2011-10-28 | -$0.35 10-Q/A · filed 2011-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |